French clinical-stage biotech firm Cellectis S.A. is developing immuno-oncology treatments using gene-edited T-cells that express chimeric antigen receptors. The company is working on multiple products including UCART19, a treatment for CD19-expressing hematologic malignancies, in addition to ALLO-501 and ALLO-501A to treat non-Hodgkin lymphoma and ALLO-715 for multiple myeloma. Cellectis S.A. is also developing UCART22, UCARTCS1 and ALLO-605 for the treatment of various leukemias and multiple myeloma. The firm has strategic partnerships with Allogene Therapeutics, Les Laboratoires Servier, and Iovance Biotherapeutics. Cellectis S.A. was founded in 1999 and is headquartered in Paris.
Cellectis S.A.'s ticker is CLLS
The company's shares trade on the NASDAQ stock exchange
They are based in Paris, France
There are 201-500 employees working at Cellectis S.A.
It is https://www.cellectis.com/en
Cellectis S.A. is in the Healthcare sector
Cellectis S.A. is in the Biotechnology industry
The following five companies are Cellectis S.A.'s industry peers: